Hailong Yan1
Shisan Bao- 1Department of Emergency Surgery, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, China
- 2Center for Evidence-based Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China
- 3Department of Hematology, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, China
Acute pancreatitis (AP) is driven by premature enzyme activation, pancreatic tissue injury, and dysregulated immune responses. IL-35 and IL-37 are key anti-inflammatory mediators whose dynamic regulation influences disease severity. Circulating IL-35 is typically upregulated in AP, functioning through STAT1/STAT4 signalling to suppress effector T-cell proliferation, inhibit Th1/Th17 differentiation, and promote expansion of regulatory T and B cells, thereby limiting pro-inflammatory cytokine release (e.g., TNF, IL-6, IL-17) and reducing local and systemic inflammation. In contrast, IL-37 is often downregulated early in AP, impairing its ability to suppress NF-κB and MAPK signalling, restrain dendritic cell and macrophage activation, and reduce gasdermin D (GSDMD)-mediated pyroptosis. Experimental restoration of IL-37 diminishes neutrophil and macrophage infiltration, mitigates pancreatic necrosis, and modulates STAT signalling. The interplay of upregulated IL-35 with insufficient IL-37, within a broader cytokine network, emphasises a compensatory yet incomplete anti-inflammatory response. IL-38, although mechanistically promising, has not yet been characterised in human or animal AP models, and its clinical translation remains hypothetical. These insights suggest that clinical strategies—such as recombinant IL-37 therapy, IL-35 modulators, or combination cytokine-targeted interventions—may restore immune homeostasis and improve outcomes in AP.
Introduction
Acute pancreatitis (AP) is an escalating global health burden and a leading cause of gastrointestinal hospitalisation (1), with an incidence of 13–45 per 100,000 annually. Gallstones, alcohol consumption, hypertriglyceridaemia, and certain medications are common triggers, while genetic and autoimmune factors contribute in specific populations (2). Chronic pancreatitis, though less frequent, often arises from long-term alcohol use, hereditary factors, or autoimmune conditions. Given marked regional and demographic variations, identifying population-specific risk factors is essential for effective prevention and management strategies. Despite advances in supportive care, AP continues to cause substantial mortality, morbidity, and healthcare costs (1, 2), highlighting the urgent need for novel therapeutic strategies, particularly those addressing the lack of immune-targeted treatments and the persistently high mortality associated with severe AP.
AP typically presents with sudden-onset severe epigastric pain radiating to the back and elevated pancreatic enzymes, with imaging modalities such as ultrasound or CT guiding diagnosis and severity assessment. Chronic pancreatitis develops more insidiously, with recurrent abdominal pain, malabsorption, and progressive endocrine insufficiency. Early recognition of severity and complications is critical for improving outcomes. Current management remains largely supportive, including fluid resuscitation, analgesia, and early nutritional support, while severe cases may require intensive care and interventions for complications (3). Experimental therapies targeting immune modulation and cytokine regulation are under active investigation to limit pancreatic injury and disease progression (4). Given this, cytokine-based immune modulation - particularly involving IL-35 and IL-37 - has emerged as a promising area of translational research.
Multiple triggers of AP (1) damage pancreatic acinar cells, causing trypsinogen leakage, premature enzyme activation, and initiation of the inflammatory cascade (2). Beyond the initial enzymatic injury, a dysregulated immune response amplifies tissue damage and provokes local as well as systemic inflammation, determining disease severity from mild oedematous pancreatitis to necrotising forms with multi-organ failure (2). Subsequently, disturbed host immune homeostasis further amplifies this injury process, with cytokines orchestrating whether inflammation resolves or escalates (5). Modulating cytokine activity – either by suppressing pro-inflammatory mediators or enhancing anti-inflammatory cytokines -significantly dictate outcomes, likely by damaging or protecting acinar cells, ducts, and infiltrating leucocytes (6). The most Recent Nobel-recognised discoveries in immune tolerance have underscored how peripheral immune regulation governs tissue-specific inflammatory diseases, offering some insight into AP pathogenesis (7). This breakthrough has substantially deepened our understanding of the mechanisms underlying the development of AP in susceptible individuals, particularly through dysregulation of the balance between pro- and anti-inflammatory responses. These seminal findings provide a stronger scientific foundation for improving the management of AP. Among cytokines maintaining this balance, IL-35 and IL-37 have emerged as key anti-inflammatory mediators with therapeutic promise in AP.
IL-35: biology and mechanistic function in AP
IL-35, a member of the IL-12 cytokine family, functions primarily as an anti-inflammatory regulator by promoting regulatory T (Treg) cells and inhibiting excessive immune responses (8). It is produced mainly by Treg cells, Breg cells, and other immune cells in response to inflammatory stimuli (9). Mechanistically, IL-35 suppresses effector T-cell proliferation, inhibits Th1 and Th17 differentiation, and promotes the expansion of Treg and Breg populations (10). In various inflammatory conditions, IL-35 exerts protective effects: it promotes M2 macrophage polarisation in psoriasis (11), reduces pathological responses in rheumatoid arthritis (12), and confers cardiovascular protection (13). IL-35 signals primarily through STAT1 and STAT4, repressing transcription of pro-inflammatory cytokines such as TNF, IL-6, and IL-17 (14), thereby limiting immune cell activation and protecting tissues.
IL-35 may mitigate pancreatic injury and modulate inflammation in patients with AP, owing to its potent anti-inflammatory activity during the acute phase of the disease. Clinical studies show circulating IL-35 is elevated in patients with AP compared with matched controls, independent of sex, age, smoking status, hypertension, hyperlipidaemia, or BMI (15). Elevated IL-35 correlates with disease severity, persisting throughout the first week, and is independent of aetiology (alcoholic, gallstone-associated, or idiopathic AP) (15). These findings suggest that IL-35 elevation reflects disease progression rather than specific triggers. Based on its anti-inflammatory properties (8, 16), IL-35 likely originates from recruited leucocytes and/or injured acinar cells as a compensatory response to inflammatory stress (15). However, such mechanisms appear insufficient to fully counteract overwhelming immune activation, such as under cytokine storms, and the precise molecular pathways remain incompletely defined.
Autoimmune pancreatitis (AIP) is a distinct immune-mediated fibro-inflammatory pancreatic disease characterised by dysregulated immune responses (2, 17). Based on the International Consensus Diagnostic Criteria, AIP is classified into two subtypes: Type I IgG4-related autoimmune pancreatitis, also termed lymphoplasmacytic sclerosing pancreatitis (LPSP), and Type II idiopathic duct-centric pancreatitis (IDCP) (18). Type I AIP represents a pancreatic manifestation of systemic IgG4-related disease, predominantly affecting adults and more frequently observed in Asian populations, and is characterised by elevated serum IgG4 levels (>135 mg/dL), abundant IgG4-positive plasma cell infiltration, an IgG4/IgG ratio >0.4, dense lymphoplasmacytic inflammation, fibrosis, and obliterative phlebitis (19, 20). IgG4’s pathogenesis involves a systemic autoimmune response, likely triggered by various microbes in gastrointestinal system, leading to massive infiltration of IgG4 plasma cells, which secrete anti-inflammatory IgG4 and pro-fibrotic cytokines, causing fibrosis, inflammation, and organ damage, involving complex T-cell (Th2/Treg) responses and characteristic storiform fibrosis and obliterative phlebitis.
In contrast, Type II AIP typically occurs in younger patients, is more prevalent in European and North American populations, lacks systemic and serological IgG4 abnormalities, and is often associated with inflammatory bowel disease. Histopathologically, Type II AIP is characterised by predominant neutrophilic infiltration with granulocytic epithelial lesions, minimal IgG4-positive plasma cells, and duct-centred epithelial injury leading to pancreatic parenchymal destruction and ductal obstruction (20). Early and accurate differentiation between these subtypes is essential for precision management and prognostic assessment.
The role of IL-35 is further illustrated, showing circulating and tissue IL-35 levels are significantly elevated in Type 1 AIP and alcoholic pancreatitis at both mRNA and protein levels (21). IL-35 correlates with other proinflammatory cytokines such as IL-27, IL-28A, and IL-29, but not with conventional biomarkers (bilirubin, amylase, liver enzymes, WBC, CRP, HbA1c). Positive correlations with IL-29 and IgG4 (21) suggest that IL-35 restrains dysregulated immunity during cytokine storms, although its ability to restore homeostasis in patients with AIP remains limited in individuals with pre-existing extensive immune dysfunction (22).
Consistent with immune dysregulation in AIP, natural Tregs (nTregs) are reduced, while effector Tregs (eTregs) are increased (21). nTregs maintain baseline immune tolerance, and their reduction may predispose to AP initiation. Acinar stress and release of damage-associated molecular patterns (DAMPs) could trigger inappropriate trypsinogen activation, promoting inflammation in genetically or immunologically susceptible hosts. In contrast, expansion of eTregs likely represents a compensatory response to ongoing inflammation. IL-35 induces inducible IL-35–producing regulatory T cells (iTr35) (23), a distinct Foxp3- regulatory T-cell subset that reinforces immunosuppression through autocrine and paracrine IL-35 signalling. A reduction in thymus-derived nTreg cells may contribute to disease initiation, whereas subsequent expansion of iTr35 cells, functionally within the eTreg compartment, appears to occur at later stages as an attempt to limit inflammatory progression, albeit insufficiently in susceptible individuals.
The positive correlation between IL-35 and IgG4 in Type 1 AIP provides mechanistic insight into the overlap between AIP and IgG4-related disease (IgG4-RD) (22). IL-35 promotes B-cell class switching to IgG4, contributing to fibrosing and chronic features of AIP. Histochemistry confirms that both Ebi3 and IL-12p35 subunits [which form IL-35 (8)] are more abundant in AIP than in alcoholic pancreatitis, reinforcing IL-35 upregulation as a compensatory response. These findings suggest IL-35 may serve as a biomarker distinguishing AIP from other forms of pancreatitis, and modulation of the IL-35–Treg–IgG4 axis could offer therapeutic potential.
Currently, the relationship between IL-35 and Type II AIP remains unexplored and warrants further investigation.
Animal models provide further mechanistic insight. Following AP onset, neutrophils and macrophages rapidly infiltrate the pancreas (24), mediated by CD18 (25). Ablation of CD18 or depletion of these cells reduces protease activation, amylase/lipase levels, and tissue damage. Anti-neutrophil serum decreases myeloperoxidase activity, and macrophage depletion reduces trypsinogen activation (24). Upregulated TNF amplifies local damage (26), enhancing pro-inflammatory responses in the affected pancreas. These findings underscore the interplay between pro-inflammatory innate immune responses and compensatory IL-35 upregulation; however, the animal model does not fully recapitulate AP or Type I/Type II AIP.
Furthermore, IL-35 also acts within a wider cytokine network, including IL-37, IL-36, and IL-38. IL-37 restrains innate immune activation (discussed below), IL-38 modulates immunity context-dependently, and IL-36 amplifies pro-inflammatory cascades (27). In AP, an imbalance between elevated IL-36 and insufficient IL-35, IL-37, and IL-38 may drive unchecked inflammation. Although IL-35 is upregulated as a compensatory response, this increase may be insufficient to restore immune balance, highlighting the need for therapies targeting multiple anti-inflammatory pathways during cytokine storms.
IL-37: biology and mechanistic role in AP
IL-37, a member of the IL-1 family, exerts context-dependent immunomodulatory effects. Intracellularly, it translocates to the nucleus, binds Smad3, suppresses transcription of pro-inflammatory genes, inhibits NF-κB and MAPK signalling, and limits activation of dendritic cells and macrophages. Extracellularly, IL-37 signals via IL-18Rα and recruits SIGIRR/IL-1R8, exerting anti-inflammatory effects under mild conditions but potentially enhancing inflammation during severe tissue injury or high cytokine burden (28). Through these dual mechanisms, IL-37 calibrates immune responses according to the intensity and context of inflammatory stress.
In AP, circulating IL-37 levels are reduced compared with healthy controls and show dynamic temporal changes. The greatest reduction occurs 72–96 hours after onset, particularly in severe AP, followed by gradual recovery, suggesting an endogenous attempt to restore homeostasis (29). Lower IL-37 levels correlate with elevated systemic inflammatory markers (LDH, CRP, IL-6), BMI, and pancreatic necrosis. ROC analysis indicates IL-37 predicts necrosis with high sensitivity (90%) and specificity (79.4%), supporting its potential prognostic utility (29).
The cellular source of IL-37 remains uncertain but may include infiltrating leucocytes and possibly acinar cells. Identifying the source and/or correlation with severity of AP, particularly at the initial stage, determining the onset of AP would really revealing the pathogenesis of host immune peripheral tolerance/intolerance. However it is almost impossible and/or inappropriate to obtain some human biopsies at appropriate stages of the development of AP, however, these are very hard to impossible to obtain, although it might be possible to have some post-mortem individuals with fulminate AP in occasional cases, the use of post-mortem AP tissues, as applied in other diseases (30), due to ethical issue, may help clarify this. Dead tissue can be obtained but this only really represents end-stage disease in most cases (there may be the occasional death in a person who is debilitated then develops AP, e.g. someone with severe heart disease who can’t handle the stress).
Animal studies provide mechanistic insight: in caerulein-induced AP, IL-37 transgenic mice show reduced necrosis, lower amylase, lipase, and IL-1β, and decreased macrophage and neutrophil infiltration (29), supporting the protective role of IL-37 in the development of AP. Such finding is in line with the data from in vitro study, recombinant IL-37 suppresses cholecystokinin-induced cell death in both the 266–6 acinar cell line and primary pancreatic acinar cells (29).
IL-37 also influences macrophage polarisation. M1/M2 balance is a key determinant of inflammatory outcomes in AP (31), and IL-37 promotes M2 polarisation, limits inflammasome activation, and restrains systemic inflammation. Recombinant IL-37 reduces gasdermin D (GSDMD)-mediated pyroptosis and modulates STAT signalling, breaking the cycle of acinar injury, DAMP release, and immune activation. GSDMD-knockout mice fail to respond, confirming IL-37’s dependence on this pathway.
Therapeutically, IL-37 - either as recombinant protein or mimetics—represents a promising approach to modulate dysregulated immunity in AP. However, the timing, administration route, and dosing require careful optimisation to maximise benefit and avoid potential pro-inflammatory effects in severe disease. Similar protective effects have been observed in cancer (31, 32), CNS autoimmunity (33), and cardiovascular injury (34), supporting broad relevance. Future studies should dissect molecular pathways mediating IL-37’s effects to guide targeted interventions.
IL-38: speculative role
IL-38 modulates immunity in a context-dependent manner, but data in AP are currently lacking. It is hypothesised that IL-38 may protect against inflammation-mediated injury synergistically with IL-35 and IL-37, warranting future investigation (35). Although mechanistic insight is limited, IL-38 could fine-tune both innate and adaptive immune responses, potentially complementing IL-37-mediated anti-inflammatory pathways.
Clinical relevance and therapeutic potential
IL-35 and IL-37 have shown protective and regulatory roles in other diseases, including in breast cancer (32), hepatocellular carcinoma (36), and inflammatory bowel disease (37). In AP, IL-35-based strategies may provide consistent anti-inflammatory effects, whereas IL-37-based therapies require careful consideration of timing, localisation, and disease severity to maximise benefit while avoiding potential pro-inflammatory outcomes.
Understanding the interplay of IL-35, IL-37, and possibly IL-38 may inform biomarker development for predicting disease severity and guiding personalised interventions. IL-37, in particular, has prognostic potential due to its temporal changes correlating with necrosis and systemic inflammation. Targeting IL-37-mediated pathways may reduce tissue injury, modulate immune responses, and limit systemic complications.
Future directions and integrative approaches
The precise sources and localisation of IL-35 and IL-37 remain incompletely defined. Identifying genes regulating their expression in pancreatic tissue, including polymorphisms or upstream signalling molecules, may provide critical insight. Integrative approaches combining graph neural networks with causal discovery represent promising strategies (38). Future studies could employ alternative causal algorithms, such as linear non-Gaussian acyclic models, and genome-wide CRISPR screens (39) to validate gene essentiality. Protein–protein interaction databases such as STRING and BioGRID may determine whether candidate genes are embedded in established regulatory modules or pathways (38).
Future studies should also employ multiplex immunohistochemistry (40) to characterise M1/M2 macrophage polarisation, assess interactions with neutrophils and other immune subsets, and monitor dynamic shifts under cytokine treatment. Mechanistically, IL-35 and IL-37 are expected to act via multiple pathways: inhibition of NF-κB and MAPK, suppression of STAT1/STAT3 transcription, restraint of NLRP3 inflammasome activation, and limitation of GSDMD-mediated pyroptosis. These interventions could reduce DAMP release and downstream cytokines, breaking the cycle of acinar injury, immune recruitment, and systemic inflammation. A schematic diagram illustrates the functional interactions of these cytokines and the associated pathways that drive the pathogenesis of AP (Figure 1).
Figure 1. The schematic diagram illustrates the key immune-mediated processes that perpetuate acute pancreatitis (AP). In the affected pancreas, there is an imbalance between pro- and anti-inflammatory factors. The anti-inflammatory response is initiated by IL-35, which promotes the expansion and function of regulatory T (Treg) cells and modulates macrophage polarization (M1 to M2), working to suppress pro-inflammatory cytokines (e.g., IL-6, TNF, IL-17). Despite these host compensatory, yet incomplete, anti-inflammatory effects, excessive inflammation persists. Concurrently, a downregulation of IL-37 expression further contributes to the imbalance between M1 and M2 macrophages and reduces the dendritic cell population. These immune alterations are mechanistically mediated through the activation of NF-κB and MAPK signalling pathways, and involve GSDMD-driven pyroptosis, collectively perpetuating local and systemic inflammatory responses characteristic of acute pancreatitis.
Limitations and safety considerations
Although exogenous IL-35 and/or IL-37 are promising therapeutic candidates, challenges remain, particularly regarding safety and systemic immunological effects. Recombinant IL-37 has shown efficacy in animal models, but comprehensive evaluation of pharmacokinetics, therapeutic efficacy, and systemic safety is still required for both cytokines. IL-38, although mechanistically promising, has not yet been characterised in human or animal AP models, and its clinical translation remains hypothetical.
Conclusion
IL-35 and IL-37 play distinct yet interconnected roles in AP. IL-35 acts as a consistent anti-inflammatory regulator by enhancing Tregs and suppressing pro-inflammatory cytokines, while IL-37 exhibits dual roles: intracellularly suppressing inflammation and extracellularly exerting protective or context-dependent effects. The balance between these cytokines likely influences AP severity, complications, and recovery. Mechanistic insights into their regulation may guide development of cytokine-based therapies to modulate inflammation, limit pancreatic injury, and improve clinical outcomes in AP.
Author contributions
HY: Writing – original draft. XD: Writing – original draft. GD: Writing – original draft. LM: Writing – review & editing. WD: Writing – review & editing. SB: Writing – review & editing. XH: Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author SB declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. AI was used in grammar and logical checking only. The authors have verified all the other points.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Iannuzzi JP, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. Gastroenterology. (2022) 162:122–34. doi: 10.1053/j.gastro.2021.09.043
2. Mederos MA, Reber HA, and Girgis MD. Acute pancreatitis: A review. JAMA. (2021) 325:382–90. doi: 10.1001/jama.2020.20317
3. Nesvaderani M, Eslick GD, and Cox MR. Acute pancreatitis: update on management. Med J Aust. (2015) 202:420–3. doi: 10.5694/mja14.01333
4. Glaubitz J, Asgarbeik S, Lange R, Mazloum H, Elsheikh H, Weiss FU, et al. Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention. Front Immunol. (2023) 14:1279539. doi: 10.3389/fimmu.2023.1279539
5. Stojanovic B, Jovanovic IP, Stojanovic MD, Jovanovic M, Vekic B, Milosevic B, et al. The emerging roles of the adaptive immune response in acute pancreatitis. Cells. (2023) 12:1–16. doi: 10.3390/cells12111495
6. Rafaqat S, Patoulias D, Behnoush AH, Sharif S, and Klisic A. Interleukins: pathophysiological role in acute pancreatitis. Arch Med Sci. (2024) 20:138–56. doi: 10.5114/aoms/178183
7. Karlén T. Nobel Prize in Physiology or Medicine 2025: They Discovered How the Immune System Is Kept in Check. (2025).
8. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine il-35 contributes to regulatory T-cell function. Nature. (2007) 450:566–9. doi: 10.1038/nature06306
9. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. Il-35-mediated induction of a potent regulatory T cell population. Nat Immunol. (2010) 11:1093–101. doi: 10.1038/ni.1952
10. Ye C, Yano H, Workman CJ, and Vignali DAA. Interleukin-35: structure, function and its impact on immune-related diseases. J Interferon Cytokine Res. (2021) 41:391–406. doi: 10.1089/jir.2021.0147
11. Zhang J, Lin Y, Li C, Zhang X, Cheng L, Dai L, et al. Il-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis. J Immunol. (2016) 197:2131–44. doi: 10.4049/jimmunol.1600446
12. Nakano S, Morimoto S, Suzuki S, Tsushima H, Yamanaka K, Sekigawa I, et al. Immunoregulatory role of il-35 in T cells of patients with rheumatoid arthritis. Rheumatol (Oxford). (2015) 54:1498–506. doi: 10.1093/rheumatology/keu528
13. Li X, Fang P, Yang WY, Wang H, and Yang X. Il-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases. Cytokine. (2019) 122:154076. doi: 10.1016/j.cyto.2017.06.003
14. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the il-35 receptor are unconventional. Nat Immunol. (2012) 13:290–9. doi: 10.1038/ni.2227
15. Zhang YL, Zhou XY, Guo XY, and Tu JW. Association between serum interleukin-35 levels and severity of acute pancreatitis. Int J Clin Exp Med. (2015) 8:7430–4.
16. Jiang Y, Wang J, Li H, and Xia L. Il-35 promotes microglial M2 polarization in a rat model of diabetic neuropathic pain. Arch Biochem Biophys. (2020) 685:108330. doi: 10.1016/j.abb.2020.108330
17. Gallo C, Dispinzieri G, Zucchini N, Invernizzi P, and Massironi S. Autoimmune pancreatitis: cornerstones and future perspectives. World J Gastroenterol. (2024) 30:817–32. doi: 10.3748/wjg.v30.i8.817
18. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. (2011) 40:352–8. doi: 10.1097/MPA.0b013e3182142fd2
19. Uchida K and Okazaki K. Current status of type 1 (Igg4-related) autoimmune pancreatitis. J Gastroenterol. (2022) 57:695–708. doi: 10.1007/s00535-022-01891-7
20. Kamisawa T and Okamoto A. Autoimmune pancreatitis: proposal of igg4-related sclerosing disease. J Gastroenterol. (2006) 41:613–25. doi: 10.1007/s00535-006-1862-6
21. Ito T, Tanaka T, Nakamaru K, Tomiyama T, Yamaguchi T, Ando Y, et al. Interleukin-35 promotes the differentiation of regulatory T cells and suppresses th2 response in igg4-related type 1 autoimmune pancreatitis. J Gastroenterol. (2020) 55:789–99. doi: 10.1007/s00535-020-01689-5
22. Perugino CA and Stone JH. Igg4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol. (2020) 16:702–14. doi: 10.1038/s41584-020-0500-7
23. Yang C, Dong L, and Zhong J. Immunomodulatory effects of itr35 cell subpopulation and its research progress. Clin Exp Med. (2024) 24:41. doi: 10.1007/s10238-024-01303-5
24. Sendler M, Dummer A, Weiss FU, Kruger B, Wartmann T, Scharffetter-Kochanek K, et al. Tumour necrosis factor alpha secretion induces protease activation and acinar cell necrosis in acute experimental pancreatitis in mice. Gut. (2013) 62:430–9. doi: 10.1136/gutjnl-2011-300771
25. Arnaout MA. Structure and function of the leukocyte adhesion molecules cd11/cd18. Blood. (1990) 75:1037–50. doi: 10.1182/blood.V75.5.1037.1037
26. Muendlein HI, Connolly WM, Cameron J, Jetton D, Magri Z, Smirnova I, et al. Neutrophils and macrophages drive tnf-induced lethality via trif/cd14-mediated responses. Sci Immunol. (2022) 7:eadd0665. doi: 10.1126/sciimmunol.add0665
27. Zhang H, Huang W, and Bao S. Dichotomous roles of il-36 and il-38 in cardiovascular disease. Front Immunol. (2025) 16:1642116. doi: 10.3389/fimmu.2025.1642116
28. Gu M, Jin Y, Gao X, Xia W, Xu T, and Pan S. Novel insights into il-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front Immunol. (2023) 14:1278521. doi: 10.3389/fimmu.2023.1278521
29. Ma N, Yuan C, Shi J, Zhu Q, Liu Y, Ma X, et al. Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis. JCI Insight. (2022) 7:4242–50. doi: 10.1007/s11426-023-1891
30. Fang BA, Dai A, Duflou J, Zhang X, Puranik R, and Bao S. Age-related inflammatory mediators in coronary artery disease (Ii). Int J Cardiol. (2013) 168:4839–41. doi: 10.1016/j.ijcard.2013.07.157
31. Ma X, Gao Y, Chen Y, Liu J, Yang C, Bao C, et al. M2-type macrophages induce tregs generation by activating the tgf-beta/smad signalling pathway to promote colorectal cancer development. Onco Targets Ther. (2021) 14:5391–402. doi: 10.2147/OTT.S336548
32. Ma Y, Su H, Wang X, Niu X, Che Y, Hambly BD, et al. The role of il-35 and il-37 in breast cancer - potential therapeutic targets for precision medicine. Front Oncol. (2022) 12:1051282. doi: 10.3389/fonc.2022.1051282
33. Yazdani R, Naziri H, Azizi G, Ciric B, Askari M, Ahmadi AM, et al. Il-37 suppresses cns autoimmunity by increasing the frequency of treg cells and reducing cd4 + T cell-derived il-10 production. J Neuroinflamm. (2024) 21:301. doi: 10.1186/s12974-024-03295-1
34. McCurdy S, Yap J, Irei J, Lozano J, and Boisvert WA. Il-37-a putative therapeutic agent in cardiovascular diseases. QJM. (2022) 115:719–25. doi: 10.1093/qjmed/hcab011
35. Zhang J, Wise SG, Zuo S, Bao S, and Zhang X. The distinct roles of il-37 and il-38 in non-small cell lung carcinoma and their clinical implications. Front Immunol. (2025) 16:1564357. doi: 10.3389/fimmu.2025.1564357
36. Ahmadnia Z, Ranaee M, Mohammadi Abandansari R, Bagheri N, and Shirzad H. Evaluating the microrna expression of il-35 and il-37 in helicobacter pylori-infected patients with gastritis and gastric ulcer. Iran J Allergy Asthma Immunol. (2022) 21:20–6. doi: 10.18502/ijaai.v21i1.8609
37. Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y, et al. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators Inflammation. (2014) 2014:136329. doi: 10.1155/2014/136329
38. Ren Z, Li X, Liu P, Li J, and Bao S. Unravelling key genes and molecular pathways in gastric inflammation-tocancer transition through causal discovery: implications for early diagnosis and therapy. SAGE Open Med. (2025) 13:1–21. doi: 10.1177/20503121251380131
39. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of crispr-cas9 essentiality screens in cancer cells. Nat Genet. (2017) 49:1779–84. doi: 10.1038/ng.3984
Keywords: acute pancreatitis, IL-35, IL-37, potential application, protective
Citation: Yan H, Dang X, Du G, Ma L, Dai W, Bao S and Huang X (2026) IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential. Front. Immunol. 17:1728737. doi: 10.3389/fimmu.2026.1728737
Received: 20 October 2025; Accepted: 23 January 2026; Revised: 22 December 2025;
Published: 09 February 2026.
Edited by:
Vlad Pădureanu, University of Medicine and Pharmacy of Craiova, RomaniaReviewed by:
Lóránd Kiss, University of Szeged, HungaryCopyright © 2026 Yan, Dang, Du, Ma, Dai, Bao and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiujuan Huang, aHVhbmd4aXVqdWFuc2hocEAxNjMuY29t; Shisan Bao, cHJvZmJhb0Bob3RtYWlsLmNvbQ==